Showing 101 - 120 results of 23,707 for search '(( a step decrease ) OR ((( 50 ((nn decrease) OR (a decrease)) ) OR ( a fold decrease ))))', query time: 0.54s Refine Results
  1. 101
  2. 102

    Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

    Published 2024
    “…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
  3. 103
  4. 104
  5. 105
  6. 106
  7. 107

    Response of small airway tissues infected with EV-D94 and decreasing doses of EV-D68. by Ines Cordeiro Filipe (5849144)

    Published 2022
    “…<p>Tissues were infected with 1E7 RNA copies of EV-D94 (equivalent to 2,46E4 TCID50) and 1E7 RNA copies of EV-D68 (3,3E5 TCID50) as well as decreasing doses of the latter. …”
  8. 108
  9. 109
  10. 110
  11. 111

    Data Preprocessing Steps for IDC Dataset. by Mudhafar Jalil Jassim Ghrabat (22177655)

    Published 2025
    “…We surpassing other models as such, CNN, VGG19, ResNet50.</p></div>…”
  12. 112
  13. 113
  14. 114
  15. 115

    Discovery and Hit-to-Lead Optimization of Benzothiazole Scaffold-Based DNA Gyrase Inhibitors with Potent Activity against Acinetobacter baumannii and Pseudomonas aeruginosa by Andrej Emanuel Cotman (5203904)

    Published 2023
    “…Starting from DNA gyrase inhibitor <b>1</b>, we identified compound <b>27</b>, featuring a 10-fold improved aqueous solubility, a 10-fold improved inhibition of topoisomerase IV from A. baumannii and P. aeruginosa, a 10-fold decreased inhibition of human topoisomerase IIα, and no cross-resistance to novobiocin. …”
  16. 116
  17. 117
  18. 118
  19. 119
  20. 120

    5-fold cross-validation comparison results. by Chunming Wen (17616274)

    Published 2025
    “…The computational cost decreased from 11.6 GFlops to 6.6 GFlops.</p></div>…”